Home

Tuesday, 30 June 2020

Covid-19 impact: Animal Genetics Market Opportunities To Reach $8.9 Billion By 2026

JUN 2020| Report Format: Electronic (PDF)

Animal Genetics Market Growth & Trends

The global animal genetics market size is expected to reach USD 8.9 billion by 2026, according to a new report by Grand View Research, Inc. exhibiting a CAGR of 4.9%. The market for animal genetics is anticipated to witness rise in demand owing to factors such as increasing consumption of animal proteins and rapid global urbanization. To fulfill the continuously rising demand, the preference for genetics to breed high-quality livestock and secure large production has increased. The demand for animal genetics has increased over the years, owing to rise in various animal diseases, increasing prevalence of zoonotic diseases, and rise in adoption of pets & companion animals.

According to Food and Agriculture Organization (FAO) publication 2017, livestock contributes almost 40% to the global value of agricultural output, and it supports food security and livelihood of more 1.5 billion people worldwide. However, the increasing land requirement for these animals and grazing is a major environmental concern. Public awareness regarding such concerns is a major reason leading to the shift toward white meat and vegan lifestyle, impeding growth of animal genetics. However, increasing support and research by government organizations to improve productivity is aiding growth. For instance; Animal Improvement Program Launched in 2014, by Animal Genomics and Improvement Laboratory (AGIL), which is an agricultural research service organization of USDA. The program aims at improving productivity and efficiency of dairy animals & ruminants.

The market follows the standards set by International Society of Animal Genetics (ISAG) and leading animal research laboratories such as The University of California Davis (U.C. Davis). The ISAG standard panel consists of 18 STR markers, and any company in animal genetics needs to follow the panel and standards set by the authorities. The need for high investments in development of new technology and the duration of product launch are some of the major factors resulting in steady growth. However, increasing population is expected to pose an ongoing challenge due to rise in the need for animal protein, aiding developments in the market.

Request a free sample copy or view report summary: 

Animal Genetics Market Report Highlights

  • Porcine segment was the largest revenue-generating segment in 2018, owing to increasing consumption of pig meat in the European countries
  • The embryo segment accounted for the largest revenue share, based on genetic material, in 2018, owing to the large numbers of embryos produced and sold in countries such as France, Canada, Brazil, and Spain
  • In the services segment, the genetic diseases testing segment accounted for the largest share in 2018 and is expected to maintain its dominance throughout the forecast period
  • The North American animal genetics market is the leading region and accounted for the largest revenue share in 2018, mainly due to existence of significant number of research and development activities in the region
  • The Asia Pacific region is expected to grow at the highest rate during the study period. Growing population coupled with increasing demand for animal protein is a major factor aiding regional growth
  • Some of the major players are Genus Plc; Envigo Corporation; Topigs Norsvin; CRV Holding B.V; Groupe Grimaud La Corbiere SA; Hendrix Genetics BV; Neogen Corporation; Zoetis, Inc; URUS; and Animal Genetics, Inc.

Covid-19 impact: Predictive Genetic Testing & Consumer/Wellness Genomics Market Is Expected At A CAGR Of 13.9% 2025

JUN 2020 | Report Format: Electronic (PDF)

The global predictive genetic testing & consumer/wellness genomics market size is expected to reach USD 8.5 billion by 2025, registering a CAGR of 13.9% over the forecast period, according to a new report by Grand View Research, Inc. Factors influencing the market progression include growing awareness about utilization of genetic tests that aid in prediction of gene susceptibility to disease development prior to symptoms. Moreover, rise in sales of these products owing to growing inclination of physicians is driving the market.

Introduction of novel platforms in next-generation sequencing technology aids in enhancing the accuracy of predictive genetic and consumer genomics kits. Market participants are engaged in implementing novel protocols to launch products that require minimal technical assistance and provide optimal customer satisfaction.

Pharmaceutical firms are engaged in several agreement models with genomic vendors for the release of novel therapeutics based on patient’s phenotypic and genotypic information. For instance, in July 2018, GlaxoSmithKline plc purchased 23andMe’s customer data to develop a new drug, thus promoting patient-centered healthcare.

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • High adoption rate of these products in clinical practice for detection of disease susceptibility resulted in the largest share of this segment in 2018
  • Growing awareness related to direct to consumer (DTC) genetic tests and entry of new players is attributive to the fastest growth of the consumer genomics segment
  • Genetic susceptibility tests are of great interest in gynecology and endocrinology-related research and diagnosis, thus allowing it to capture the maximum revenue share. These tests enable the identification of susceptible genes or mutations in adenomyosis, endometriosis, and postmenopausal osteoporosis
  • Application of predictive genetic and consumer genomics is highest in the detection of breast and ovarian cancer as these tests hold the potential to identify BRCA mutations in patients
  • Advent of predictive tests for identification of MLH1, MSH2 genes for colorectal cancer diagnosis is expected to fuel market growth in the coming years
  • Colorectal screening initiatives such as mass screening and population-based screening are expected to boost segment growth
  • North America dominated the market with the largest revenue share in 2018 owing to the presence of major players and high adoption rate
  • Asia Pacific is expected to witness substantial growth in the coming years owing to increasing adoption of these products in developing economies
  • Manufacturers contributing significantly to market growth include Pathway Genomics; ARUP Laboratories; BGI; Illumina, Inc.; 23andMe, Inc.; Color Genomics Inc.; and Myriad Genetics, Inc. Established as well as emerging companies are involved in adopting strategic moves for the launch of novel products.

Covid-19 impact: Medical Device Analytical Testing Outsourcing Market Is Expected At A CAGR Of 11.6% 2025

JUN 2020 | Report Format: Electronic (PDF)

The global medical device analytical testing outsourcing market size is expected to reach USD 8.3 billion by 2025, according to a new report by Grand View Research, Inc. A large number of medical device companies outsource analytical testing operations to minimize business risks, hasten product market entry, and reduce costs. These lead to significant rise in expenditure levels and, therefore, medical device original equipment manufacturers rapidly switch to outsourcing as one of the effective cost curbing tool.

Implantable Medical Devices (IMDs) are being used increasingly in order to improve patients’ health outcome. Designers of IMDs have to balance complexity, reliability, power consumption, and costs. Consequently, companies are shifting their focus to innovation rather than noncore activities and, therefore, outsourcing these activities to launch efficient devices. All these factors are expected to increase the medical device outsourcing market over the forecast period.

In this complex ecosystem, it is necessary for equipment to provide accurate results, to have durability, and easy operation. To match these parameters, devices now have to undergo shear testing in accelerated conditions to obtain marketing approval and have competitive advantage. Conducting these in-house is matter of time, labor, and cost; outsourcing these tests helps overcome these limitations.

U.S. medical device analytical testing outsourcing market, by services 2014–2025 (USD Million)

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • Material characterization dominated the medical device analytical testing outsourcing market in 2015 and is likely to grow at a lucrative rate during the forecast period
  • Other tests that are inclusive of cleaning, reprocessing, method development & validation, accelerated stability testing, biocompatibility, validation testing for packaging materials (container closure permeation), and transport stability are also anticipated to witness rewarding growth.
  • North America is likely to witness lucrative growth which is attributed to the fact that it is one of the top manufacturing hubs of highly reliable, complex, and high-end medical devices.
  • Some of the key players operating in this space are SGS SA; Toxikon, Inc.; Eurofins Scientific; Pace Analytical Services, LLC; Intertek Group plc; WuXi AppTec.; NORTH AMERICAN SCIENCE ASSOCIATES INC.; Envigo; Charles River Laboratories International Inc.; and Medical Device Testing Services

Covid-19 impact: Pharmaceutical Analytical Testing Outsourcing Market Is Expected At A CAGR Of 8.3% 2025

JUN 2020 | Report Format: Electronic (PDF)

The global pharmaceutical analytical testing outsourcing market size is expected to reach USD 11.4 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 8.3% over the forecast period. Increasing pipelines for biological candidates, rising demand for additional analytical details on drugs, and process development by regulatory agencies are boosting the market growth.

Analytical testing helps in providing real-time product quality control along with optimizing and monitoring processes, characterizing biosimilars and biologics, and improving productivity. One of the main reasons for outsourcing analytical testing services is to benefit from skilled and experienced professionals, as well as to access expensive analytical equipment which are not available in-house.

Increased development of biologics is also creating a demand for analytical testing services. In the last three decades, biologics have taken the center stage in the discovery and development of drugs. Moreover, there is a high demand to define higher-order biological structures. The need for better product characterization, along with comparability studies, especially for biosimilars, further leads to drug companies outsourcing these services.

A patent cliff, particularly for small molecules in the pharmaceutical industry leads to a decline in revenue, thereby affecting profits. Over the next few years, several best-selling biologics would come toward the end of patent life, such as Humira. Drug innovators are therefore under constant pressure to bring new products through the pipeline at a faster rate. Developing advanced analytical testing to assess and monitor the quality attributes of these products requires a broader set of equipment and expertise, which is beyond the internal capacity of pharma companies. This would subsequently lead to increased instances of outsourcing pharmaceutical analytical testing services.

To request a sample copy or view summary of this report, click the link below:
www.grandviewresearch.com/industry-analysis/pharmaceutical-analytical-testing-outsourcing-market

Further key findings from the report suggest:

  • The outsourcing of clinical bioanalytical testing services emerged as the largest segment in 2019 with a share of around 79% owing to the increasing number of clinical trials
  • The extractable and leachable services segment is expected to witness a significant growth rate owing to an increasing number of vendors offering these services at competitive prices
  • North America dominated the global market with a share of 54.2% in 2019 as the region is one of the top manufacturing hubs of highly reliable, complex, and high-end pharmaceuticals
  • Some of the players operating in the pharmaceutical analytical testing outsourcing market are Toxikon, Inc.; Intertek Group PLC; SGS SA; Eurofins Scientific; Boston Analytical; Pace Analytical Services, LLC; West Pharmaceutical Services, Inc.; Intertek Group Plc; Pharmaceutical Product Development, LLC; WuXi AppTec, Inc.; and Charles River Laboratories International, Inc.

Covid-19 impact: Medical Marijuana Market Is Expected At A CAGR Of 17.1% 2025

JUN 2020 | Report Format: Electronic (PDF)

The global medical marijuana market is expected to reach a value of USD 55.8 billion by 2025, according to a new report by Grand View Research, Inc. It has been identified that, in 2016, Washington D.C. along with 28 states have legalized marijuana for medical uses. In 2016, states such as Arkansas, Florida, North Dakota, Ohio, and Pennsylvania were approved to use the drug in medical applications such as chemotherapies and pain management. The growing number of states and countries getting approval for using it in therapeutic applications is one of the crucial factors driving the demand over the coming few years.

The presence of several regulatory frameworks such as the Medical Marijuana Regulation and Safety Act is indicators of the present demand for the drug in the market. The regulatory framework requires every individual or the company associated such as growers, retail operators, and makers of processed pot products to obtain permission and an annual state license from 2018. An increasing number of issued licenses is also among factors that is expected to drive the market especially after 2018.

The increasing interest amongst the academic researchers and healthcare providers regarding the therapeutic uses of marijuana is among the significant factors, which is driving the market over the coming years. Some of its potential therapeutic values are suppression of vomiting & nausea, pain relief, and appetite stimulation. In addition, research states that marijuana is effective in providing relief to the patient suffering from HIV/AIDS, glaucoma, cancer, and multiple sclerosis. The growing number of therapeutic applications of the drug is one of the key factors that is propelling the market over the forecast period.

U.S. medical marijuana market by application, 2013–2025 (USD Billion)

To request a sample copy or view summary of this report, click the link below:
www.grandviewresearch.com/industry-analysis/medical-marijuana-market

Further key findings from the study suggest:

  • In 2015, chronic pain was the largest application segment owing to the presence of a huge patient base
  • The growing prevalence of chronic pain elevates the demand for the drug, thus expected to boost the medical marijuana for chronic pain management
  • The rapidly growing number of cannabis legalization in the U.S. is one of the key attributes for its increased demand in therapeutic and recreational uses, and thus anticipated to impel the market growth
  • Increasing investment in R&D & demand for cannabis in chemotherapy is expected to drive the growth in the Asia Pacific market
  • Some of the key players are Cara Therapeutics Inc.; CannaGrow Holdings, Inc.; Cannabis Sativa, Inc.; United Cannabis Corporation; GrowBlox Sciences, Inc.; GW Pharmaceuticals, plc; Lexaria Corp; International Consolidated Companies, Inc.

Covid-19 impact: Radiation Dose Monitoring Market Is Expected At A CAGR Of 8.2% 2025

JUN 2020 | Report Format: Electronic (PDF)

Global radiation dose monitoring market size is anticipated to reach a value of USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. The advantage of automated dose monitoring systems to track individual and cumulative radiation dose exposure in patients is driving significant demand for the product.

Dose monitoring is achieved by the use of software and designated products such as dosimeters. Dose management software analyzes, identifies, and optimizes radiation dose performance with precise data. This data aids the physicians to provide quality care to the patients. Furthermore, easy integration of software into existing medical architecture of hospitals will boost the value of existing medical systems and ensure safety of using them.

Area of application commonly employing the use of medical imaging is radiography, angiography, mammography, fluoroscopy & interventional imaging and nuclear medicine. Several medical imaging technology manufacturers are constantly involving in the incorporation of the radiation dose monitoring tools in these imaging platforms. X-ray and computed tomography technique are known to emit a large amount of radiation as compared to other imaging platforms. The overall market exhibits promising growth prospects pertaining to high prevalence of chronic diseases, effective and reliable treatment methods focusing on care, and increasing patient awareness.

U.S. radiation dose monitoring market, by application, 2014–2025 (USD Million)

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • North America reported highest revenue growth in this market in 2015. A shift to the value based care delivery model has resulted in healthcare providers to divert their attention to deliver healthcare services concentrating on the well-being of a patient
  • Asia Pacific region provides lucrative market opportunities for radiation dose monitoring. Significant factors such as rapid urbanization, upgrade in healthcare infrastructure and delivery will further support the radiation dose monitoring market growth in emerging economies like India and China
  • The market for radiation dose monitoring software is expected to generate strong revenue growth in the fiscal year 2015. The software market enables easy integration to existing architecture in healthcare facilities, and will sync into the integrated care delivery benefitting the specialists to provide better and monitored care
  • The major market players recognized in this market are GE Healthcare, Sectra, Medicvision, Philips Healthcare, Toshiba MSC, Bayer AG, Landauer, Inc. and Thermo Fisher Scientific, Inc.

Covid-19 impact: Latin America Pharmaceutical Contract Manufacturing & Research Services Market Analysis To Reach $21 Billion By 2025

JUN 2020 | Report Format: Electronic (PDF)

The Latin American pharmaceutical contract manufacturing & research services market is anticipated to reach USD 21.0 billion by 2025, according to a new report by Grand View Research, Inc. Low drug registration cost in Latin American countries and continuous economic growth are the key factors contributing to progress in this region. Moreover, Latin America offers higher recruitment rates and relatively high competitive prices in comparison to United States and other European countries.

A forementioned fact pronounces the trend of shifting Contract Manufacturing/Research Organizations (CMO/CRO)’s attention to Latin American countries such as Brazil, Mexico, Argentina, and Colombia. Ongoing adjustment in Latin America to reduce the commodity prices and domestic political turbulence in each country is expected to shape region’s economic growth there by driving revenue generation in the outsourcing market for pharmaceutical development.

Mexico pharmaceutical contract manufacturing services market, by service type, 2014–2025 (USD Million)

To request a sample copy or view summary of this report, click the link below:

Further Key Findings from the study suggest:

  • Contract manufacturing services accounted for the largest share owing to wide range of services offered by the CMO’s located herein for therapeutic drug development
  • API/Bulk drug development services accounted for the largest share over the other segments as companies continue to invest for API production capacity enhancement
  • Rising inclination of drug manufacturers to focus on core competencies such as R&D are observed to have a major impact on the yearly growth of contract research organizations
  • Brazil held the largest share with respect to revenue generation in 2015
  • Government’s current initiative to ensure GMP compliance among small and medium-sized pharma companies has contributed for the large share of Brazil
  • Chile is expected to witness the fastest growth over the forecast period.
  • Presence of companies offering bioanalytical, biomarker discovery, assay development, and cGMP analytical services can be attributed for the estimated growth
  • Key players contributing in this market are Lonza; Charles River Laboratories S.A; Jubilant Life Sciences Limited; Boehringer Ingelheim GmbH; Pfizer, Inc. (Pfizer CenterOne); Albany Molecular Research, Inc; QuintilesIMS; and Pharmaceutical Product Development, LLC.
  • These entities are involved in collaborations with therapeutic research organizations in order to enhance their industrial presence

Covid-19 impact: Liposomal Doxorubicin Market Analysis To Reach $1.39 Billion By 2024

JUN 2020 | Report Format: Electronic (PDF)

The global liposomal doxorubicin market is expected to reach a value of USD 1.39 billion by 2024, according to a new report by Grand View Research, Inc. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.

The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.

Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.

U.S. liposomal doxorubicin market, by product, 2013–2024 (USD Million)

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • The increasing number of mergers & acquisitions and partnerships for clinical trials on technologically advanced doxorubicin formulations will boost market growth
  • Increasing investment in Asia Pacific pertaining to the R&D, improving healthcare infrastructure, and heightened patient cognizance regarding targeted cancer therapies and chemotherapy will drive regional market growth
  • Key players operating in the market are Janssen Products; LP; Teva Pharmaceuticals; Sun Pharmaceutical Industries Ltd.; Pfizer, Inc.; Cipla, Inc.; Cadila Pharmaceuticals; and SRS Pharmaceuticals Pvt. Ltd.

Monday, 29 June 2020

Covid-19 impact: Osteosynthesis Devices Market Analysis To Reach $9.9 Billion By 2024

JUN 2020 | Report Format: Electronic (PDF)

Osteosynthesis Devices Market Growth & Trends

The osteosynthesis devices market size is expected to reach a value of USD 9.9 billion by 2024, according to a new report by Grand View Research, Inc. The worldwide prevalence of conditions like osteoporosis and osteomalacia, coupled with heavily occurring road traffic injuries/accidents and sporting injuries support the demand for osteosynthesis devices worldwide.

Osteoporosis, a disease resulting in weakening of bones is responsible for causing more than 8.9 million fractures annually. Forearm, humerus, hip and spine are the most commonly affected areas in patients suffering from the disease. The incidence and economic burden of osteoporosis is increasing worldwide, and patients 65 years old or over are at maximum risk of getting affected.

The geriatric population accounted for 46.2 million in 2014, and is increasingly rising. It is projected that by the year 2060, the number of older population will be twice than that of 2014. The rising incidence of osteoporosis and increasing count of the geriatric population is expected to drive demand for osteosynthesis devices in the coming years.

On the other hand, road traffic deaths are at the focal point of a crisis facing public health and development. The WHO reported that accidents/injuries majorly affect the low- and middle-income countries. Road accidents can cause severe injuries such as broken bones and fractures and requires immediate orthopediccare and attention.

Global Osteosynthesis Devices Market Summary size

Request a free sample copy or view report summary: 
www.grandviewresearch.com/industry-analysis/osteosynthesis-devices-market/request/rs1

Osteosynthesis Devices Market Report Highlights

  • North America reported highest revenue growth in this market. U.S. is one of the most lucrative and commercially important markets for orthopedic device manufacturers. Furthermore, technical advancements and a growing aging population (14.5% of the U.S. population), coupled with increasing investments in healthcare sector is estimated to drive growth in the market.
  • Asia Pacific is expected to be an attractive region for osteosynthesis devices. Asia Pacific is reported to be at a high risk for osteoporosis because of a reported rise in the elderly population.
  • Internal fixation devices held a higher market share than external devices in 2015. Although complications such as infections, consolidation delays, and construct damage are causing concerns, this has indirectly led to the demand for new research and management options in the fight against osteoporosis and fractures.
  • The development of absorbable and biocompatible internal bone fixation devices is responsible for leading the drive for constant innovation in the osteosynthesis devices market.
  • Some of the key players in this industry include DePuy Synthes, Inc.; Smith & Nephew Plc; Stryker; Zimmer Biomet Holdings, Inc.; Globus Medical, Inc.; GS Medical, LLC; Life Spine, Inc.; MicroPort Orthopedics, Inc.; Néosteo SAS; and Precision Spine, Inc.

Covid-19 impact: Dental Practice Management Software Market Is Expected At A CAGR Of 10.2% 2027

JUN 2020 | Report Format: Electronic (PDF)

The global dental practice management software market size is expected to reach USD 3.8 billion by 2027, expanding at a CAGR of 10.2% during the forecast period, based on a new report by Grand View Research, Inc. Market growth can be attributed to the increasing geriatric population along with an expected increase in oral healthcare expenditure and in number of dental practices.

According to the U.S. Census Bureau’s International Data Base, the population of individuals who are 45 years and older is expected to grow by about 12.0% between 2015 and 2025, while the total U.S. population will increase by about 8.0% during the same period. Furthermore, the expected increase in oral health insurance coverage and favorable government initiatives could drive the market during the forecast period.

The usage of various modules increases the productivity and efficiency of dentists. Furthermore, technological advancements in the field and growing investments by companies in emerging economies are expected to propel market growth. Integrated software solutions help in streamlining the dental practices.

Mergers and acquisitions for the development and commercialization of products are likely to drive market growth in the coming years. In 2018, Henry Schein, Inc., formed Henry Schein One, LLC in a joint venture with Internet Brands, a software company. The new company was launched with an intention to provide integrated dental technology to medical practitioners in order to improve patient communication and practice management.

To request a sample copy or view summary of this report, click the link below:

Further key findings from the report suggest:

  • By deployment mode, the web-based segment dominated the dental practice management software market in 2019 owing to the reasonable pricing structure. The cloud-based segment may surpass the web-based and on-premise segments over the coming years owing to the additional advantages
  • The cloud-based dental practice management software segment is projected to grow at the fastest rate during the forecast period. This is due to its flexibility, disaster recovery system, automatic software updates, increased collaboration, ability to work on any internet connected device, security, environment-friendly features, and ability to establish competition
  • By end use, the dental clinics segment accounted for the largest market share in 2019 and is expected to exhibit the fastest CAGR over the forecast period
  • In 2019, North America dominated the global market due to favorable government initiatives, local presence of key players, growing geriatric population, and high oral healthcare expenditure
  • Asia Pacific is expected to grow at the fastest rate over the forecast period owing to increasing investments by industry players and rising awareness about oral healthcare
  • Some of the market players operating in the industry are Henry Schein, Inc.; Patterson Companies, Inc.; Carestream Dental; Curve Dental, Inc., DentiMax, LLC; Practice Web, Inc.; NextGenHealthcare Information Systems, LLC; and ACE Dental Software.

Covid-19 impact: Immunohematology Market Opportunities To Reach $2.3 Billion By 2024

JUN 2020 | Report Format: Electronic (PDF)

The global immunohematology market size is expected to reach a value of USD 2.3 billion by 2024, according to a new report by Grand View Research, Inc. This expansion is attributed to the increasing cases of trauma and rising number of hospital and trauma care centers facilitating emergency treatments. This creates a need to procure blood to suffice the demand, thus, boosting the market for immunohematology tests and products.Involvement of government organizations and NGOs is vast in this field.

Use of technology is contributing to the growth in the market. Use of mobile applications helps in tracking the blood donation activity of volunteer donors and also reminds them to donate regularly. In April 2016, The Indian Red Cross Society launched an application (app) to facilitate blood banking facility. The app is expected to address the shortage issue in the region. Moreover, in 2011, the first type of this application was launched by Hemo bioscience, Inc., a U.S.-based company. The company made the app available for free for apple users.

U.S. immunohematology market by product, 2013–2024 (USD Million)

To request a sample copy or view summary of this report, click the link below:

Further Key Findings From the Study Suggest:

  • Immunohematology reagents dominated the product segment in 2015 due to huge product variety and an increasing number of blood banks procuring these reagents. The innovations in the field are resulting in new product launches and also the efforts are acknowledged at a global level.
  • In December 2013, Sysmex Corporation received the German Design Award for its XN-2000 hematology reagent. Almost 1,900 products were nominated for the award.
  • Hospitals dominated the end-use segment in 2015 due to increasing number of emergency cases because of road accidents and other types of trauma. Governments and investors are increasingly investing in expanding and upgrading emergency departments in hospitals to cater to the growing demand and increase the chances of survival of trauma patients.
  • In 2015, North America dominated the immunohematology market with a revenue share of more than 40%. In the U.S., there is a patient requiring transfusion every 2 seconds. The daily consumption of blood is approximately 36,000 units per day. This indicates the huge opportunity of growth in this region.
  • Some of the key industry players are Hologic, Inc., Bio-Rad Laboratories, Inc.; Grifols, ThermoFisher, Immucor; Ortho Clinical Diagnostics; BD (Becton Dickinson); Siemens Healthcare GmbH; Abbott; and Beckman Coulter, Inc.

Covid-19 impact: Pharmerging Market Is Expected At A CAGR Of 17.1% 2025

JUN 2020 | Report Format: Electronic (PDF)

The global pharmerging market is expected to reach USD 2,231.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure.

According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0–40.0% of the prescription drug market, and 40.0–50.0% of the OTC drug market.

Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.

The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

To request a sample copy or view summary of this report, click the link below:
www.grandviewresearch.com/industry-analysis/pharmerging-market

Further Key Findings from the Study Suggest:

  • Pharmaceutical segment was the major contributor for the pharmerging market in 2016.
  • Pharmaceutical sector also recorded the fastest growth in the pharmerging industry.
  • Tier I is driving growth in the pharmerging market.
  • India among the Tier II countries is estimated to witness the fastest growth in the pharmerging industry.
  • Brazil was recorded as the major contributor for Tier II countries.
  • Among Tier III countries, Nigeria and Indonesia are estimated to be driving growth.
  • The key players include Sanofi, Pfizer Inc., AstraZeneca, GlaxoSmithKline, F.Hoffmann-La Roche, GE Healthcare, Eli Lilly, Medtronic, Johnson and Johnson, Abbott.
  • The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.

Covid-19 impact: Hospital Information Systems Market Is Expected At A CAGR Of 11.4% 2026

JUN 2020 | Report Format: Electronic (PDF)

The global hospital information systems market size is expected to reach USD 39.7 billion by 2025 according to a new report by Grand View Research, Inc. The growing demand to reduce the wastage of healthcare budgets, minimize the risk of errors, and streamline the workflow of hospitals for improved outcomes are the key contributors to the market expansion.

There is a paradigm shift from traditional approach of paper-based manual operations to paperless IT-based solutions in hospital management. The growing number of government initiatives across the globe is accelerating the deployment of such technology. In 2016, the National Governors Association Center for Best Practices Health Division published a roadmap with an aim of improving the exchange of critical health data across different health entities.

The IT companies and healthcare organizations are collaborating at a greater level to develop high utility services and products to improve overall hospital administration. For instance, IBM and Cleveland Clinic have announced their 5-year agreement to expand Cleveland Clinic’s health IT technologies. Another example is partnership between Hospira and Latric Systems to work toward developing two-way communication between EMRs andHospira’s smart infusionpumps.

Technological advancements such as adoption of EHR, eHealth platforms, cloud computing, Picture Archiving and Communication System (PACS), Radiology Information Systems (RIS), web-based technology, Software as a Service (SaaS) are gaining momentum in the medical sector.

U.S. hospital information systems market by delivery mode, 2013–2025 (USD billion)

To request a sample copy or view summary of this report, click the link below:
www.grandviewresearch.com/industry-analysis/hospital-information-systems-his-market

Further Key Findings from the Study Suggest:

  • In 2015, cloud-based technology was the dominating segment owing to cost considerations and data storage capacity
  • Software segment was the leading segment in 2015 due to growing need for IT infrastructure in hospital management
  • North America dominated the market in 2015. The U.S. is the largest market in North America due to the high adoption of such systems as a result of government initiatives and sophisticated healthcare facilities
  • Asia Pacific is expected to be the fastest growing owing to the improving infrastructure in the emerging economies, increasing government spending on healthcare, and rising adoption of advanced technologies
  • The market dynamics indicate the presence of strong competition amongst the key players like Carestream Health; GE Healthcare; Philips Healthcare; Cerner Corporation; NextGen Healthcare; Merge Healthcare (IBM), and many others

Covid-19 impact: General Surgery Devices Market Size to surge at 8.5% CAGR is expected to reach $26.5 Billion in 2026

JUN 2020 | Report Format: Electronic (PDF)

The global general surgery devices market size is expected to reach USD 26.5 billion by 2026 registering a CAGR of 8.5%, according to a new report by Grand View Research, Inc. Increasing number of surgical procedures being performed coupled with technological advancements is anticipated to drive the market. Moreover, rising awareness and patient affordability for plastic or reconstructive surgeries would propel the number of procedures conducted during the forecast period.

Global health initiatives for the advanced surgical procedure is expected to boost the market. In January 2017, Ethiopia Federal Ministry of Health (FMOH) launched the Health Sector Transformation Plan (HSTP) and Safe Surgery (SaLTS) program that prioritizes safe surgery and makes anesthesia care and emergency surgical services accessible and affordable.

Technological advancements are also contributing to the market growth. Several key companies are investing in R&D for the development of innovative products. For instance, development of medical robots to assist surgeons is a key advancement in the field. Medical robots offer several advantages, such as a 3D view of the operating field, reduced blood loss & transfusions, lower risk of infection, faster recovery time, minimal scarring, and high precision.

Furthermore, growing aging population and cases of road accidents and increased healthcare expenditure in emerging economies are likely to boost the market during the forecast period. According to the WHO, the world’s population aged 60 years and above is expected to reach 2 billion by 2050 from 900 million in 2015. Geriatric population is more susceptible to a number of diseases, which is likely to increase the need for effective treatments, thereby driving the market.

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • Disposable surgical supplies held the largest market share in 2018. Low product cost and regulatory support for the usage of disposable products is expected to fuel the demand for these devices
  • Asia Pacific is estimated to expand at the highest CAGR over the forecast period due to technological advancements, increasing investments and improving reimbursement scenario along with the growing medical tourism sector in the region
  • Medical robotics & computer-assisted surgery devices are projected to witness the maximum CAGR of 9.9% from 2019 to 2026 due to increasing R&D investments and availability of technologically advanced products
  • Some of the key companies in the market are Medtronic plc; Johnson & Johnson Services, Inc.; CONMED Corp.; Becton, Dickinson and Company (BD); B Braun Melsungen AG; Strykers; Boston Scientific Corp.; Erbe Elektromedizin GmbH; and The 3M Company

Covid-19 impact: HIV-1 Therapeutics Market Analysis To Reach USD 15.8 Billion By 2025

JUN 2020 | Report Format: Electronic (PDF)

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients’ medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

U.S. HIV-1 therapeutics market revenue, by drug class, 2014–2025 (USD Billion)

To request a sample copy or view summary of this report, click the link below:

Further Key Findings from the Study Suggest:

  • NRTIs were the largest class of drugs available in the market in 2015 accounting for over 40% of total drugs available in this vertical
  • Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.
  • In 2015, North America held the largest market share in 2015 with a share of over 35%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.
  • Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth
  • Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.
  • Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Covid-19 impact: Negative Pressure Wound Therapy Market Analysis To Reach $4.0 Billion By 2025

JUN 2020 | Report Format: Electronic (PDF)

The global negative pressure wound therapy market size is anticipated to reach a value of USD 4.0 billion by 2025, according to a new report by Grand View Research, Inc. Increasing awareness in the developing regions pertaining to advanced wound care is providing a significant opportunity to the key market players to cater to the unmet needs of the target population. The primary driver associated with this market is the cost-effectiveness of single-use negative pressure wound therapy (NPWT) devices .

Major companies are also focusing on education of reimbursement coveragein such regions to further increase the affordability of these devices. However, the current reimbursement policies mostly cover conventional NPWT devices owing to their high cost.Furthermore, the geriatric population is also contributing to a great extent toward increasing the prevalence of chronic diseases. Increasing age is one of the high risk factorsleading to the development of chronic diseases such as atherosclerosis, which is one of the prime cardiovascular disorders prevalent in the geriatric population.

NPWT is one of the commonly accepted therapies employed for the treatment of arterial ulcers, which is one of the major complications of atherosclerosis. Around 50% of the people worldwide are exposed to fire-related traumas, among which, 90% of the cases occur in low to moderate income countries.Thus, the rising incidence of traumatic events is expected toengender a high demand for negative pressure wound therapy products.

China NPWT market by wound type, 2014–2025 (USD Million)

To request a sample copy or view summary of this report, click the link below:

Further Key Findings from the Study Suggest:

  • Conventional NPWT devices dominated the product segment in 2015 owing to their high cost and availability of favorable reimbursement policies
  • Single-use negative pressure wound therapy devices segment is considered to be the fastest growing segment over the forecast period
  • Diabetic foot ulcer held the largest revenue share in 2015 owing to its numerous applications,thus yielding a high success rate using NPWT
  • Homecare setting is anticipated to witness an attractive CAGR over the forecast period owing to the emerging applicability of single-use NPWT devices in the homecare setting and cost-effectiveness of the therapy
  • North America dominated the overall negative pressure wound therapy market in 2015. This is primarily due to the increased usage of the target therapy in this region, which has led to a reduction in hospital stays and contributed toward enhanced quality of patient lives
  • Some key companies in this market are Acelity L.P. Inc., Smith & Nephew, Mölnlycke Health Care, Talley Group Limited, ConvaTec Inc., Devon Medical, Cardinal Health, Inc., DeRoyal Industries, Inc., Medela AG and Paul Hartmann AG

Friday, 26 June 2020

Covid-19 impact: Track And Trace Solutions Market Is Expected At A CAGR Of 18.5% 2027

JUN 2020 | Report Format: Electronic (PDF)

The global track and trace solutions market size is expected to reach USD 8.2 billion by 2027, according to a new report by Grand View Research, Inc., registering an 18.5% CAGR over the forecast period. The growth is attributed majorly due to increasing focus of pharmaceutical and biopharmaceutical companies on ensuring brand protection from counterfeit products and theft. The deployment of track and trace solutions helps manufacturers enhance distribution channel efficiency and reduces the frequency of counterfeit products.

Rising adoption of track and trace solutions by healthcare device and product manufacturers will fuel market growth in the long run. Introduction of advanced technologies, such as RFID, provides fast reading and delivers high levels of security. However, deployment cost of serialization and aggregation systems, as well as lack of common regulations and standards, may hamper market growth in some developing regions.

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • By product, software formed the largest revenue-generating segment in the market in 2019. This is mainly because of regulatory mandates for the execution of serialization and aggregation in the healthcare sector
  • The serialization application was the largest grossing segment in 2019. Increasing application of serialization in pharmaceuticals and medical devices packaging will be a vital factor contributing to segment growth
  • Based on technology, the RFID segment is expected to exhibit the fastest growth rate during the study period. Key factors contributing to segment growth are technological advantages such as high durability and reusability, more data storage capacity, and no requirement of line of sight
  • North America is dominated the global market in 2019. Rising implementation of regulatory standards and regulations, along with high adoption rate of track and trace solutions by consumers is anticipated to contribute to market growth
  • Some of the key players in the track and trace solutions market are Axway; Mettler-Toledo International, Inc.; Optel Vision; Adents International; Antares Vision srl; TraceLink, Inc.; Siemens AG; ACG Worldwide, Seidenader Maschinenbau GmbH; and Systech, Inc.

Covid-19 impact: Sepsis Diagnostics Market Size to surge at 9.4% CAGR is expected to reach $1.1 Billion in 2027

JUN 2020 | Report Format: Electronic (PDF)

The global sepsis diagnostic market size is expected to reach a value of USD 1.1 billion by 2027, expanding at a CAGR of 9.4%, according to a new report by Grand View Research, Inc. High prevalence of sepsis, introduction of technologically advanced medical examination systems and increasing government initiatives is expected to propel market growth over the forecast period.

According to CDC estimates, every year more than 1.7 million adults in U.S. suffer from sepsis, which leads to around 270,000 deaths. Furthermore, according to the report published by OECD in 2018, every year around 3.8 million patients suffer from hospital-acquired infections (HAIs) in acute care hospitals in European countries. High prevalence of HAIs in key regions is expected to significantly increase the demand for medical examination solutions, thereby fueling market growth over the forecast period.

Increasing regulatory approval and introduction of technologically advanced medical examination solutions for the life-threatening disease condition are expected to facilitate market growth over the forecast period. In May 2018, T2 Biosystems, Inc., a U.S.-based emerging medical examination solutions company received the U.S. FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens.

In April 2019, the Scottish Government in collaboration with Sepsis Research (originally called FEAT — The Fiona Elizabeth Agnew Trust) launched a Scotland-wide campaign to spread public awareness about the signs and symptoms of sepsis. Such initiatives to raise public awareness about the disease condition is expected to raise demand for its rapid medical examination solutions and support its market growth in the near future.

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • In 2019, the blood culture media segment has emerged as the largest revenue generating segment owing to the high adoption of culture media tests in laboratories for the diagnosis of septic poisoning
  • Molecular diagnostics is anticipated to witness a lucrative CAGR over the forecast period owing to its high sensitivity, accuracy, and less turnaround time
  • In 2019, bacterial sepsis contributed towards the largest revenue share among the pathogen segment owing to its high prevalence
  • North America dominated the sepsis diagnostics market with the largest revenue share in 2019. High awareness, favorable reimbursement scenario, and presence of established players are facilitating the dominance of this region during the study period
  • The Asia Pacific region is projected to witness a lucrative growth owing to increasing awareness about sepsis diagnosis and treatment in emerging economies such as India and China
  • Some of the key players include bioMérieux SA; Beckman Coulter, Inc.; Becton, Dickinson and Company; Sysmex Corporation; F. Hoffmann-La Roche AG; and Thermo Fisher Scientific, Inc.

Covid-19 impact: Biotechnology/Pharmaceutical Services Outsourcing Market Opportunities To Reach $92.9 Billion By 2025

JUN 2020 | Report Format: Electronic (PDF)

The global biotechnology services outsourcing market is expected to reach USD 92.9 billion by 2025, according to a new report by Grand View Research, Inc. Pharmaceutical industry has been adaptive of the function of outsourcing certain clinical and corporate functions as early as 2002. Among the services outsourced, clinical trial management and contract manufacturing were the forerunners. For instance, Johnson & Johnson was the first pharmaceutical company to outsource its applications development and maintenance (ADM).

In 2015, over USD 50.0 billion was spent on pharmaceutical R&D activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected to propel the biotechnology services outsourcing market growth over the forecast period.

Shrinking profit margins coupled with rising competition in the market space, and augmenting regulatory burden are other vital impact rendering factors. The pharmaceutical services outsourcing market is expected to register growth at a CAGR of 8.7% during the forecast period. On the other hand, pending immigration legislations in the U.S. may hinder business economics and outsourcing risks.

Pharmaceutical and biotechnology industries in Europe are significantly investing in R&D in the recent year owing to rising demand for advanced medicines. This may be attributed to increasing aging population, incidence of chronic diseases, and communicable diseases.

U.S. biotechnology services outsourcing market by service, 2014–2025 (USD Billion)

To request a sample copy or view summary of this report, click the link below:

Further key findings from the study suggest:

  • Consulting services are inclusive of regulatory compliance, remediation, and quality management systems consulting, which is expected to dominate the pharmaceutical services outsourcing market in 2025.
  • In 2013, the U.S. FDA revised the guidelines for registration trials of drugs used in the treatment of acute bacterial skin and skin structure infections, thereby promoting growth of regulatory affairs services.
  • Other services such as contract manufacturing, product upgrade, and IT consulting services are projected to grow swiftly. Increasing focus on generic medicine and regional expansions in developing regions are some of the key contributing factors
  • Presence of cheap labor, skilled personnel and rapid growth of the pharmaceutical industry within the Asia Pacific region presents numerous opportunities for service providers, thereby representing a lucrative growth rate over the forecast period.
  • Service based expertise may be found in players such QuintilesIMS, Parexel Corporation, Lachman Consultant Services, Inc., Concept Heidelberg GmbH, and others. These players compete on the basis of service quality, competitive pricing, and long-term relations with healthcare industry participants.

Covid-19 impact: Healthcare Augmented & Virtual Reality Market Is Expected At A CAGR Of 29.1% 2025

JUN 2020 | Report Format: Electronic (PDF)

Healthcare Augmented & Virtual Reality Market Growth & Trends

The global augmented reality & virtual reality in healthcare market is expected to reach USD 5.1 billion by 2025 according to a new report by Grand View Research, Inc. The growing adoption of Augmented Reality (AR) & Virtual Reality (VR) in medical field, increasing investments in such emerging technologies, and constant developments in healthcare IT are some of the key factors responsible for growth of this market.

The market is majorly driven by applications in surgical simulations, diagnostic imaging, patient care management, rehabilitation, and health management. The application of AR & VR in training medical professionals provides them enhanced understanding of anatomy & physiology and assists in complicated surgeries that require precision, thus, resulting in reduced complications and lesser trauma. VR helps patients get over their worst fears and phobias through the exposure therapy. These technologies are also gaining significance in fitness management due to the development of various health apps that help train doctors as well as patients.

The use of these advanced technologies in live streaming of surgeries for medical education coupled with patient monitoring & pain management serves as a market opportunity and is predicted to drive the segment substantially. These new disruptive technologies have revolutionized medical field and provide an innovative approach for transforming healthcare experience. The increasing focus on streamlining medical operations along with demand for better delivery of care services are driving the growing adoption of these technologies.

Increase in number of startups has led to higher demand for investments to fund development of AR & VR technologies. The market is witnessing an increase in private investments by various investors, which is expected to boost growth further. For instance, Swiss-based startup MindMaze is a well-funded company that has raised USD 100 million from Hinduja Group for development of VR hardware & software. In addition, increased government funding and supportive initiatives are expected to drive growth.

North America augmented reality & virtual reality in healthcare market, by technology, 2014–2025 (USD Million)

Request a free sample copy or view report summary:
www.grandviewresearch.com/industry-analysis/virtual-reality-vr-in-healthcare-market

Healthcare Augmented & Virtual Reality Market Report Highlights

  • The hardware segment held the majority of the revenue share in 2016 due to rise in adoption of wearable devices in healthcare
  • AR dominated the technology segment in 2016 owing to its increasing adoption in surgeries and medical training
  • North America dominated the global market for AR and VR due to greater adoption of advanced technology and sophisticated infrastructure
  • Asia Pacific AR and VR market is expected to witness a lucrative growth of 33% over the forecast period
  • Some of the key players include CAE HEALTHCARE; GE Healthcare; Intuitive Surgical; Hologic, Inc.; Virtual Realities, LLC; and Philips Healthcare
Subscribe to: Posts (Atom)